Keyword search (4,163 papers available)

"Soucy JP" Authored Publications:

Title Authors PubMed ID
1 Associations between brain and cognitive resilience, tau load and extent in Alzheimer's disease Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; 41512332
PERFORM
2 Alzheimer s Imaging Consortium Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; 41433447
PERFORM
3 The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterbe 41020412
SOH
4 The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterberg H; S 40778177
PSYCHOLOGY
5 Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; 39893139
CONCORDIA
6 Alzheimer's Imaging Consortium Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; 39782975
CONCORDIA
7 Biomarkers Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; 39784152
CONCORDIA
8 Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; 38006502
PERFORM
9 Increased brain cholinergic innervation in isolated REM sleep behaviour disorder from prodromal multiple system atrophy Wickens RH; Postuma RB; de Villers-Sidani É; Pelletier A; Blinder S; Gagnon JF; Soucy JP; Montplaisir J; Bedard MA; 37939636
PERFORM
10 Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum Belasso CJ; Cai Z; Bezgin G; Pascoal T; Stevenson J; Rahmouni N; Tissot C; Lussier F; Rosa-Neto P; Soucy JP; Rivaz H; Benali H; 37920382
PERFORM
11 Dosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans Thiel A; Kostikov A; Ahn H; Daoud Y; Soucy JP; Blinder S; Jaworski C; Wängler C; Wängler B; Juengling F; Enger SA; Schirrmacher R; 37870640
PERFORM
12 Lactate's behavioral switch in the brain: An in-silico model Soltanzadeh M; Blanchard S; Soucy JP; Benali H; 37865309
PERFORM
13 A person with frontotemporal dementia shows increased metabolic rate across multiple brain regions after a series of tDCS sessions Roncero C; Nikelski J; Soucy JP; Lahiri D; Seixas-Lima B; Chertkow H; 37182684
PERFORM
14 Primary and Secondary Progressive Aphasia in Posterior Cortical Atrophy Brodeur C; Belley É; Deschênes LM; Enriquez-Rosas A; Hubert M; Guimond A; Bilodeau J; Soucy JP; Macoir J; 35629330
IMAGING
15 Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A; 35420022
PERFORM
16 Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [(18)F]-FEOBV Legault-Denis C; Aghourian M; Soucy JP; Rosa-Neto P; Dagher A; Aumont E; Wickens R; Bedard MA; 34628195
PERFORM
17 CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; 33532543
PERFORM
18 Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E 33401137
PERFORM
19 Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants 32725777
PERFORM
20 Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, 32582834
PERFORM
21 Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography. Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ 32353194
PERFORM
22 Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P 31530809
PERFORM
23 Development of "[11C]kits" for a fast, efficient and reliable production of carbon-11 labeled radiopharmaceuticals for Positron Emission Tomography. Jolly D, Hopewell R, Kovacevic M, Li QY, Soucy JP, Kostikov A 28038410
PERFORM
24 Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment. Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J 28522082
PERFORM
25 Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with 18F-FEOBV. Bedard MA, Aghourian M, Legault-Denis C, Postuma RB, Soucy JP, Gagnon JF, Pelletier A, Montplaisir J 31078078
PERFORM
26 Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers. Booij L, Welfeld K, Leyton M, Dagher A, Boileau I, Sibon I, Baker GB, Diksic M, Soucy JP, Pruessner JC, Cawley-Fiset E, Casey KF, Benkelfat C 26905412
PSYCHOLOGY
27 Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging. DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E 27578494
PERFORM
28 Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry. Khalili-Mahani N, Rombouts SA, van Osch MJ, Duff EP, Carbonell F, Nickerson LD, Becerra L, Dahan A, Evans AC, Soucy JP, Wise R, Zijdenbos AP, van Gerven JM 28145075
PERFORM
29 Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA 28894304
PERFORM
30 Altered Regional Cerebral Blood Flow in Idiopathic Hypersomnia. Boucetta S, Montplaisir J, Zadra A, Lachapelle F, Soucy JP, Gravel P, Dang-Vu TT 28958044
PERFORM
31 Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative 29396637
PERFORM
32 Altered brain perfusion patterns in wakefulness and slow-wave sleep in sleepwalkers. Desjardins MÈ, Baril AA, Soucy JP, Dang-Vu TT, Desautels A, Petit D, Montplaisir J, Zadra A 29514303
PERFORM
33 Impaired sensorimotor processing during complex gait precedes behavioral changes in middle-aged adults. Mitchell T, Starrs F, Soucy JP, Thiel A, Paquette C 30247510
PERFORM

 

Title:Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.
Authors:Aghourian MLegault-Denis CSoucy JPRosa-Neto PGauthier SKostikov AGravel PBédard MA
Link:https://www.ncbi.nlm.nih.gov/pubmed/28894304?dopt=Abstract
DOI:10.1038/mp.2017.183
Publication:Molecular psychiatry
Keywords:
PMID:28894304 Category:Mol Psychiatry Date Added:2019-04-15
Dept Affiliation: PERFORM
1 Université du Québec à Montréal (UQAM), Cognitive Pharmacology Research Unit, Montreal, QC, Canada.
2 McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, QC, Canada.
3 McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Verdun, QC, Canada.
4 Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
5 PERFORM Centre, Concordia University, Montreal, QC, Canada.

Description:

Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

Mol Psychiatry. 2017 11;22(11):1531-1538

Authors: Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Abstract

18F-fluoroethoxybenzovesamicol (FEOBV) is a new PET radiotracer that binds to the vesicular acetylcholine transporter. In both animals and healthy humans, FEOBV was found sensitive and reliable to characterize presynaptic cholinergic nerve terminals in the brain. It has been used here for we believe the first time in patients with Alzheimer's disease (AD) to quantify brain cholinergic losses. The sample included 12 participants evenly divided in healthy subjects and patients with AD, all assessed with the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) cognitive scales. Every participant underwent three consecutive PET imaging sessions with (1) the FEOBV as a tracer of the cholinergic terminals, (2) the 18F-NAV4694 (NAV) as an amyloid-beta tracer, and (3) the 18F-Fluorodeoxyglucose (FDG) as a brain metabolism agent. Standardized uptake value ratios (SUVRs) were computed for each tracer, and compared between the two groups using voxel wise t-tests. Correlations were also computed between each tracer and the cognitive scales, as well as between FEOBV and the two other radiotracers. Results showed major reductions of FEOBV uptake in multiple cortical areas that were evident in each AD subject, and in the AD group as a whole when compared to the control group. FDG and NAV were also able to distinguish the two groups, but with lower sensitivity than FEOBV. FEOBV uptake values were positively correlated with FDG in numerous cortical areas, and negatively correlated with NAV in some restricted areas. The MMSE and MoCA cognitive scales were found to correlate significantly with FEOBV and with FDG, but not with NAV. We concluded that PET imaging with FEOBV is more sensitive than either FDG or NAV to distinguish AD patients from control subjects, and may be useful to quantify disease severity. FEOBV can be used to assess cholinergic degeneration in human, and may represent an excellent biomarker for AD.

PMID: 28894304 [PubMed - indexed for MEDLINE]





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University